EGFR and lip and oral cavity carcinoma: Recently, cetuximab, a mouse-human chimeric mAb (IgG1) that targets epidermal growth factor receptor (EGFR), was approved by the Food and Drug Administration (FDA) in the USA for treatment of oral cancers (41).